FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912595787> ?p ?o ?g. }

• W2912595787 endingPage "142" @default.
• W2912595787 startingPage "132" @default.
• W2912595787 abstract "Over the last 25 years many biological therapeutics have been approved for clinical use, and many of these for diseases where there was no other available therapy. There has been an evolution over this time period from proteins intended to be ‘nature identical’ to the development of engineered products and use of novel protein scaffolds intended to confer a pharmacokinetic, pharmacodynamic or other advantage over the natural counterpart. In addition, protein engineering has allowed the development of monoclonal antibodies as highly potent modulators directed at specific peptides/proteins. Monoclonal antibodies are generally considered to have a long elimination half-life, due to the protective mechanism of FcRn binding; however, target mediated drug disposition is often observed whereby clearance changes with dose, particularly with antibodies directed against cell surface targets. This phenomenon where the kinetics of the target itself can impact the kinetic behaviour of the therapeutic protein is one of the key differences between small molecule drugs and monoclonal antibodies. Another key difference is the potential for immunogenicity with therapeutic proteins where anti-drug-antibodies are produced against what the body recognises as a ‘foreign’ protein. Immunogenicity can impact both the pharmacokinetic (PK) and pharmacodynamic (PD) behaviour of the therapeutic protein, as well as the safety profile. Many of these molecules demonstrate exquisite species selectivity in their biological activity and the species used for preclinical safety assessment should be selected with this in mind. The ability to extrapolate to human from preclinical data needs to take into account this potential species specificity. Differences in potency across species can be greater than safety margins imposed on either dose or exposure and should be factored into appropriate dose selection for entry into clinical testing. For this reason, it is important to select the starting dose for first-in-human trials based on an understanding of both the toxicological and pharmacological dose–concentration-effect relationships. The latter has resulted in an increased emphasis on translational PK-PD approaches to the design of preclinical studies and the translation of PK-PD data to support early clinical development. Such approaches require the development of an integrated suite of PK, PD and immunogenicity bioanalytical assays to support preclinical and clinical development." @default.
• W2912595787 created "2019-02-21" @default.
• W2912595787 creator A5012606324 @default.
• W2912595787 creator A5036182931 @default.
• W2912595787 date "2013-04-18" @default.
• W2912595787 modified "2023-10-14" @default.
• W2912595787 title "Biological Therapeutics" @default.
• W2912595787 cites W1970247466 @default.
• W2912595787 cites W1975871632 @default.
• W2912595787 cites W1980650956 @default.
• W2912595787 cites W2009743786 @default.
• W2912595787 cites W2023749561 @default.
• W2912595787 cites W2024304683 @default.
• W2912595787 cites W2046271895 @default.
• W2912595787 cites W2050162659 @default.
• W2912595787 cites W2050427803 @default.
• W2912595787 cites W2050869931 @default.
• W2912595787 cites W2051291954 @default.
• W2912595787 cites W2071595419 @default.
• W2912595787 cites W2071843728 @default.
• W2912595787 cites W2080335269 @default.
• W2912595787 cites W2082425581 @default.
• W2912595787 cites W2102456247 @default.
• W2912595787 cites W2116619489 @default.
• W2912595787 cites W2138906847 @default.
• W2912595787 cites W2141989396 @default.
• W2912595787 cites W2161278243 @default.
• W2912595787 cites W2162826734 @default.
• W2912595787 cites W2165068832 @default.
• W2912595787 cites W2322800034 @default.
• W2912595787 cites W88754920 @default.
• W2912595787 doi "https://doi.org/10.1002/9781118532331.ch6" @default.
• W2912595787 hasPublicationYear "2013" @default.
• W2912595787 type Work @default.
• W2912595787 sameAs 2912595787 @default.
• W2912595787 citedByCount "0" @default.
• W2912595787 crossrefType "other" @default.
• W2912595787 hasAuthorship W2912595787A5012606324 @default.
• W2912595787 hasAuthorship W2912595787A5036182931 @default.
• W2912595787 hasConcept C111113717 @default.
• W2912595787 hasConcept C112705442 @default.
• W2912595787 hasConcept C147816474 @default.
• W2912595787 hasConcept C159654299 @default.
• W2912595787 hasConcept C161624437 @default.
• W2912595787 hasConcept C181199279 @default.
• W2912595787 hasConcept C185592680 @default.
• W2912595787 hasConcept C203014093 @default.
• W2912595787 hasConcept C2780035454 @default.
• W2912595787 hasConcept C2780868878 @default.
• W2912595787 hasConcept C542903549 @default.
• W2912595787 hasConcept C55493867 @default.
• W2912595787 hasConcept C64903051 @default.
• W2912595787 hasConcept C70721500 @default.
• W2912595787 hasConcept C74187038 @default.
• W2912595787 hasConcept C86803240 @default.
• W2912595787 hasConcept C98274493 @default.
• W2912595787 hasConceptScore W2912595787C111113717 @default.
• W2912595787 hasConceptScore W2912595787C112705442 @default.
• W2912595787 hasConceptScore W2912595787C147816474 @default.
• W2912595787 hasConceptScore W2912595787C159654299 @default.
• W2912595787 hasConceptScore W2912595787C161624437 @default.
• W2912595787 hasConceptScore W2912595787C181199279 @default.
• W2912595787 hasConceptScore W2912595787C185592680 @default.
• W2912595787 hasConceptScore W2912595787C203014093 @default.
• W2912595787 hasConceptScore W2912595787C2780035454 @default.
• W2912595787 hasConceptScore W2912595787C2780868878 @default.
• W2912595787 hasConceptScore W2912595787C542903549 @default.
• W2912595787 hasConceptScore W2912595787C55493867 @default.
• W2912595787 hasConceptScore W2912595787C64903051 @default.
• W2912595787 hasConceptScore W2912595787C70721500 @default.
• W2912595787 hasConceptScore W2912595787C74187038 @default.
• W2912595787 hasConceptScore W2912595787C86803240 @default.
• W2912595787 hasConceptScore W2912595787C98274493 @default.
• W2912595787 hasLocation W29125957871 @default.
• W2912595787 hasOpenAccess W2912595787 @default.
• W2912595787 hasPrimaryLocation W29125957871 @default.
• W2912595787 hasRelatedWork W1591820460 @default.
• W2912595787 hasRelatedWork W1899411185 @default.
• W2912595787 hasRelatedWork W1934038313 @default.
• W2912595787 hasRelatedWork W1978032370 @default.
• W2912595787 hasRelatedWork W1979757582 @default.
• W2912595787 hasRelatedWork W2329258414 @default.
• W2912595787 hasRelatedWork W2332367370 @default.
• W2912595787 hasRelatedWork W2400461952 @default.
• W2912595787 hasRelatedWork W3154750840 @default.
• W2912595787 hasRelatedWork W79555446 @default.
• W2912595787 isParatext "false" @default.
• W2912595787 isRetracted "false" @default.
• W2912595787 magId "2912595787" @default.
• W2912595787 workType "other" @default.